{"schema_version":"secwatch.filing_event.v1","accession":"0001937653-22-000011","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.989092+00:00","generated_at":"2026-06-22T04:38:26.913008+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Zymeworks Q3 net loss $47.8M; announces zanidatamab deal with Jazz up to $1.76B","bullets":["Licensed zanidatamab to Jazz for up to $1.76B total payments plus 10-20% tiered royalties; $50M upfront expected 4Q22.","Q3 revenue $2.6M (down from $4.4M), net loss $47.8M (vs $60.6M YoY).","Cash $166.2M; Jazz upfront extends cash runway through at least 2026.","Phase 1 zanidatamab zovodotin showed 31% ORR at 2.5 mg/kg Q3W; manageable tolerability.","Aims to file 5 INDs in next 5 years; IND for ZW191 (FRα-ADC) expected 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001937653-22-000011","json":"https://secwatch.observer/filing/0001937653-22-000011.json","markdown":"https://secwatch.observer/filing/0001937653-22-000011.md","text":"https://secwatch.observer/filing/0001937653-22-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000193765322000011/0001937653-22-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000193765322000011/zyme-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:38:26.913008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b58ffdcbbe3db1cea11c354f625186dc72f72487","claim":"Zymeworks Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"today reported financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937653/000193765322000011/0001937653-22-000011-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}